Search Bar & Filters
Found 86 Actively Recruiting clinical trials
Actively Recruiting
Researchers are comparing three treatments for adults with obstructive sleep apnea OSA to find which works best and is easiest to use regularly. This study evaluates traditional positive airway pressure PAP therapy, a dental device, and a combination of two FDA-approved medications atomoxetine and oxybutynin that are used for other conditions. Participants must have a recent OSA diagnosis and symptoms such as snoring or daytime sleepiness. Participants will be randomly assigned to one of three groups using a PAP machine, wearing a dental device during sleep, or taking the medication combination. These treatments are studied over one year to assess their effectiveness and ease of use. The study includes two in-person visits and four phone check-ins during this time. During the study, participants will complete surveys, report side effects, and discuss treatment adherence. Researchers will measure quality of life, sleep apnea severity, sleep impairment, blood pressure changes, treatment adherence, and side effects at 12 months. The total participation lasts one year with regular monitoring to understand how each treatment impacts health and daily life.
Actively Recruiting
Researchers are studying the safety and appropriate dosing of special immune cells called autologous CART cells, specifically DSG3-CAART and CABA-201, in adults with active pemphigus vulgaris PV, a painful autoimmune disease causing blisters on skin and mucous membranes. This phase 12 open-label trial includes patients with mucosal and mucocutaneous forms of PV, focusing on those not well controlled by standard treatments. Participants receive either DSG3-CAART through single or multiple intravenous infusions at different dose levels, or CABA-201 as a single intravenous infusion, sometimes combined with preconditioning treatments like cyclophosphamide and fludarabine. The DSG3-CAART part of the study is no longer enrolling, while the CABA-201 sub-study is ongoing. These treatments are being evaluated for safety and how they affect the disease. During the trial, participants undergo various assessments including monitoring for adverse events up to three months for DSG3-CAART and up to 28 days or longer for CABA-201. Researchers track immune cell levels, autoantibody changes, disease activity scores, clinical remission status, and other biomarkers for up to 36 months or longer. The study includes regular evaluations to understand the treatment effects and safety over time.
Actively Recruiting
Researchers are evaluating the efficacy and safety of HBS-301 in adults aged 18 years and older who have idiopathic hypersomnia IH, a condition characterized by excessive daytime sleepiness EDS. This Phase 3 clinical trial is randomized, double-blind, and placebo-controlled, aiming to better understand how HBS-301 affects the severity of sleepiness and other IH symptoms compared to placebo. Participants will be randomly assigned to receive either HBS-301 tablets or matching placebo tablets once daily in the morning upon waking during an 8-week double-blind treatment period. After this, participants may choose to join an optional 1-year open-label extension where all receive HBS-301. The study begins with a screening and baseline period lasting up to 28 days, followed by 30 days of safety follow-up after treatment ends. During the trial, participants will have regular assessments including questionnaires measuring sleepiness severity using the Epworth Sleepiness Scale and other scales evaluating IH symptoms, sleep inertia, fatigue, cognition, quality of life, and work productivity. Safety monitoring includes tracking any adverse events throughout the 16 months of the study. Participants will be involved in scheduled visits for evaluations and treatment adherence, with the primary focus on changes in daytime sleepiness severity over the 8-week treatment period.
Actively Recruiting
Researchers are conducting a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the effectiveness and safety of HBS-301 in adults aged 18 years and older with narcolepsy. The study focuses on treating excessive daytime sleepiness EDS, cataplexy, sleepinesswakefulness, and fatigue in this population. Participants will be randomly assigned to receive either HBS-301 tablets or matching placebo tablets once daily in the morning upon waking during an 8-week double-blind treatment period. After this, participants may opt into a one-year open-label extension where all receive HBS-301. The study begins with a screening and baseline period lasting up to 28 days, followed by the treatment phases, and concludes with a 30-day safety follow-up. During the study, participants will undergo various assessments including the Epworth Sleepiness Scale to measure changes in daytime sleepiness, evaluations of cataplexy frequency, fatigue levels, sleepinesswakefulness tests, and quality of life questionnaires. Safety will be monitored throughout the entire study duration of approximately 16 months. Participants will have scheduled visits for assessments during each phase to track treatment effects and safety.
Actively Recruiting
Researchers are investigating the safety and early effectiveness of CTX112, a new type of immune therapy, in adults with difficult-to-treat autoimmune diseases such as systemic lupus erythematosus SLE, systemic sclerosis SSc, and idiopathic inflammatory myopathy IIM. This Phase 1, open-label study involves multiple centers and focuses on patients who have not responded to other treatments. CTX112 uses genetically modified donor T cells designed to target CD19, a protein involved in these diseases. Participants receive CTX112 through an intravenous infusion after preparation with lymphodepleting chemotherapy to help the therapy work effectively. The study uses an ascending dose design, meaning doses may increase over time to evaluate safety and response. This treatment is given in a single arm, meaning all participants receive CTX112, with no placebo or comparison group. During the study, participants will attend scheduled visits for treatment and monitoring. Assessments include safety evaluations for 28 days after infusion and longer-term follow-up for up to 60 months to study the therapys effects on disease activity, drug behavior in the body, and overall response. Participants will have regular laboratory tests, clinical evaluations, and follow-up visits to track their health and treatment outcomes throughout the study.
Actively Recruiting
Researchers are evaluating the drug efruxifermin EFX in adults with compensated cirrhosis caused by NASH Nonalcoholic Steatohepatitis or MASH Metabolic Dysfunction-Associated Steatohepatitis. This phase 3, randomized, double-blind, placebo-controlled study aims to assess the safety and efficacy of EFX in slowing disease progression and improving liver health over several years. Participants will be randomly assigned to receive either EFX 50 mg or a placebo, both given by subcutaneous injection. The study includes two cohorts one with biopsy-proven compensated cirrhosis and metabolic features, and another diagnosed either by biopsy or non-invasive methods. Treatment and follow-up will continue for up to five years to monitor outcomes. Throughout the study, participants will undergo regular assessments including liver fibrosis markers, liver injury markers, lipoproteins, insulin sensitivity, glycemic control, and body weight changes. Safety will be closely monitored through laboratory tests, ECGs, ultrasounds, and vital signs. The primary outcome measures include time to significant clinical events like disease progression or liver decompensation and improvements in fibrosis and steatohepatitis, with follow-up extending up to five years.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of efruxifermin EFX in adults with non-cirrhotic nonalcoholic steatohepatitis NASH or metabolic dysfunction-associated steatohepatitis MASH who have moderate to advanced liver fibrosis stage 2 or 3. This Phase 3, multi-center study randomly assigns participants to different treatment groups and compares EFX with a placebo to see its impact on liver health and related clinical outcomes. Participants are divided into two groups one with about 750 subjects having confirmed NASHMASH and fibrosis stage 2 or 3, and another with about 900 subjects with fibrosis stage 3 regardless of their NAFLD activity score. They receive either 28 mg or 50 mg of EFX or a matching placebo through weekly injections under the skin. The study includes a screening period up to 12 weeks, a 52-week treatment phase for the first group, a 96-week phase for the second group, and an extended follow-up period lasting up to around 240 weeks, plus a follow-up visit about a month after the last dose. During the study, participants undergo liver biopsies, blood tests, imaging scans like FibroScan, and assessments of liver fibrosis markers and metabolism-related measures. Researchers monitor changes in liver tissue, liver function tests, cholesterol, blood sugar control, body weight, and safety indicators over time. Even if participants stop the study drug early, they may continue with scheduled assessments to support long-term evaluation of treatment effects and safety throughout the study duration.
Actively Recruiting
Researchers are evaluating DR-01, a non-fucosylated human immunoglobulin G1 monoclonal antibody, in adult patients with large granular lymphocytic leukemia or various cytotoxic lymphomas. This first-in-human, multicenter Phase 12 study aims to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of DR-01 in these patient populations. The study is sponsored by Dren Bio and involves sequential dose escalation and expansion cohorts to find the optimal treatment regimen. Participants will receive DR-01 at different starting doses ranging from 0.3 mgkg to 10 mgkg, following one of three dosing schedules during the first month bi-weekly dosing, dosing on days 1, 8, 15, and 29, or dosing on days 1-5, 15, and 29. After the first month, dosing continues monthly with doses adjusted up to 10 mgkg for up to 25 cycles. Dose escalation and de-escalation cohorts are included, and optimized dosing regimens are evaluated separately for leukemia and lymphoma subjects in expansion phases. Throughout the study, participants will be monitored for adverse events, dose-limiting toxicities, and overall response rates using disease-specific criteria. Safety and pharmacological assessments will occur up to 25 months, with special focus on the first 28 days for dose-limiting toxicities and up to 6 months for dose optimization. Participants will undergo regular evaluations including clinical assessments and tissue biopsies when applicable. The study aims to determine the best dosage while closely monitoring safety and treatment effects over two years.
Actively Recruiting
Idiopathic Hypersomnia IH is a condition where adults feel extremely sleepy during the day, especially in the morning, even after sleeping a lot at night. This condition can cause difficulty waking up, trouble focusing, and symptoms like dizziness. Researchers are studying TAK-360, a drug that acts like orexin, a brain chemical that helps keep people awake. The study aims to understand how safe and tolerable TAK-360 is for adults with IH and to find the right dose to help with wakefulness. Participants in the study will be randomly assigned to receive either TAK-360 tablets or placebo tablets that look the same but contain no active medicine. Both treatments will be taken orally for 4 weeks. The study uses a double-blind design, meaning neither participants nor researchers know who receives the drug or placebo, to fairly evaluate the effects of TAK-360. During the study, participants will be monitored for safety and side effects up to 8 weeks. Researchers will measure changes in daytime sleepiness using the Epworth Sleepiness Scale and symptoms using the Idiopathic Hypersomnia Severity Scale at the start and after 4 weeks. The trial will also track any treatment-emergent adverse events. The total participation time may include screening, treatment, and follow-up assessments over several weeks.
Actively Recruiting
Narcolepsy Type 1 NT1 is a sleep disorder characterized by excessive daytime sleepiness and sudden muscle weakness while conscious, known as cataplexy. This trial evaluates the safety and tolerability of TAK-360 in adults with NT1. Participants must stop their current NT1 medications before starting the study treatment. They may be randomly assigned to receive either TAK-360 or a placebo, which looks identical but contains no active medicine. The trial is sponsored by Takeda and uses a randomized, double-blind design. Participants will take TAK-360 or matching placebo tablets orally. The study includes multiple parts where participants receive either TAK-360 or placebo in a parallel design. After the treatment period lasting up to about 28 weeks, participants will be monitored for an additional two weeks. Following study treatment, participants can resume their usual NT1 medications. Throughout the trial, participants will visit the clinic multiple times for evaluations. Researchers will assess treatment-emergent adverse events, sleep latency using the Maintenance of Wakefulness Test, sleepiness levels with the Epworth Sleepiness Scale, and weekly cataplexy rates. Safety and tolerability will be closely monitored, and participants usual care will continue after the study ends.
1-10 of 86
1